newsroom /

Milan, Italy Mar. 23, 2022

KLISBio to share its leading-edge silk-based technology platform at 2022 AAOS Annual Meeting

Milan, Italy (March 23, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The event will be held March 22-26 in Chicago -IL. KLISBio’s designated attendee to 2022 AAOS Congress is Jason Schense, CBO and COO.

Significant challenges in treating peripheral nerve injuries persist within the domain of surgery and regenerative medicine, having a profound impact on patients’ quality of life. KLISBio is committed to contributing to the advancement of orthopedics with SILKBridge, its first product in pipeline intended for the surgical repair of digital nerves.

SILKBridge, a silk-based graft, is a tissue-engineered technology made of pure silk fibroin. It has the potential to show an optimized balance between biomechanical and biological properties, complementing the high strength of native silk fibers and the enhanced biomimicry of electrospun silk. It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. KLISBio is working with a world-renowned panel of KOLs in hand surgery both in US and EU with the aim to make SILKBridge a competitive solution for peripheral nerve repair. SILKBridge is anticipated to be available for clinical use in the US market in 2023.

“SILKBridge is expected to have noticeable results on treatment of peripheral nerve injuries and represents our commitment to disrupting the current restorative surgical market. KLISBio is leveraging silk as a powerful and biocompatible scaffold material, targeting different clinical indications in the orthopedic, vascular and drug release markets via several technology platforms.”, said Jason Schense, CBO and COO.

KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.

KLISBio is powered by an international group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer; Giuliano Freddi, Chief Scientific Officer; Jason Schense, Chief Business Officer and Chief Operating Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades’ experience in global healthcare.

About KLISBio:

KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.